Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy
Executive Summary
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.
You may also be interested in...
Senate Finance Drug Pricing Bill May Gain Traction As Panel’s Lead Health Staffer Joins CMS
Arielle Woronoff joins the Biden Administration after four years of steering health policy at the Senate Finance Committee, including work on the Grassley-Wyden bill.
Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Medicare CAR-T Payment Policy Walks Line Between Innovation and Cost Concerns
CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement.